Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XDx, a molecular diagnostic company, has announced that it is cutting down 25 jobs as part of restructuring its business. It is also undertaking other cost saving measures in response to the current economic situation.
Subscribe to our email newsletter
The company will focus on maximizing the current market opportunity for the FDA cleared AlloMap product, restructure its internal development program and pursue external research collaborations in lupus, as well as suspend development activities in lung transplant.
XDx has also said that it will increase its research, development and commercial activities in support of AlloMap in the heart transplant market, while continuing selected activities in autoimmunity.
Pierre Cassigneul, XDx’s CEO, said: “The decision to restructure XDx is a difficult but necessary step given the current economic environment in which we are operating. We believe the steps we are taking to reprioritize our efforts and realign the organization will strengthen the company in the short run and position us for long-term success.”